Aktienanalyse zu Coherus Oncology Inc (CHRS)CHRSCoherus Oncology Inc

Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Coherus BioSciences Inc (CHRS) appears to be a good buy at the current price of $0.7494, especially considering its RSI of 23.693, indicating it is oversold. The company has a strong gross margin of 70.35% in Q2 2026, which suggests efficient cost management and potential for profitability as revenues grow. However, the main risk is the forward P/E of 41.1523, indicating high expectations for future earnings that may not materialize, especially given the recent net income losses.

8 analysts cover CHRS: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.50.